Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term azetukalner safety and efficacy study in major depressive disorder
2025-523618-10-00Phase 3Authorised
- Sponsor
- Xenon Pharmaceuticals
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in major depressive disorder (MDD), sponsored by Xenon Pharmaceuticals. Primary endpoint: Severity and frequency of TEAEs, SAEs, AESIs, and ECIs. Planned start Jun 2026; status: authorised.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2025-523618-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523618-10-00.